Physician profile
Mark Fergeson
NPI 1497170526
$1,672.37
in general payments reported to CMS, 2019-2025
14 companies · $898 in 2025
The $898 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $125 · 2022: $26.92 · 2023: $42.21 · 2024: $581 · 2025: $898.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,520.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,520.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $376.75 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $262.09 | 2024-2025 | Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $186.41 | 2025 | Caplyta |
| Pfizer INC. | $174.35 | 2025 | |
| Amgen INC. | $147.21 | 2024-2025 | Repatha, Otezla, Repatha |
| Supernus Pharmaceuticals, INC. | $142.29 | 2024 | Qelbree |
| Astellas Pharma US INC | $130.16 | 2024 | Veozah |
| Gilead Sciences, INC. | $125.00 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $49.65 | 2022-2024 | Rexulti |
| Idorsia Pharmaceuticals US INC | $21.45 | 2024 | Quviviq |
| Acella Pharmaceuticals, LLC | $15.81 | 2025 | NP Thyroid 60 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.22 | 2023 | Xifaxan |
| Lilly USA, LLC | $13.05 | 2023 | Jardiance |
| Nestle Healthcare Nutrition INC. | $12.93 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Fergeson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.